Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Beigene Ltd (ADR)    BGNE

BEIGENE LTD (ADR) (BGNE)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Beigene : Chinese cancer-drug maker BeiGene in US$1.4 billion tie-up with biotech giant Celgene

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/29/2017 | 02:17pm CEST

BeiGene, a Chinese maker of cancer medicines, has closed a US$1.39 billion deal with the American biotechnology giant Celgene, marking the biggest overseas licensing to date of drugs developed in China.

The deal will bankroll BeiGenes clinical trials for treating the four most common tumours in China lung, stomach, liver and eosophageal cancers said Wang Xiaodong, co-founder and chairman of the companys scientific advisory board.

Under the agreement, BeiGene will receive an aggregate of US$413 million from Celgene in upfront licensing fees and equity investment, with an additional US$980 million in future regulatory and sales proceeds.

In exchange, the global biopharmaceutical firm will receive exclusive rights to commercialise BeiGenes immuno-oncology therapy, BGB-A317, in the United States, Europe, Japan and the rest of the world outside Asia.

BeiGene will assume Celgenes operations in China including its approved products for treating breast cancer, multiple myeloma and myelodysplastic syndrome both forms of blood cancer.

The partnership would combine our geographical strength to ensure a broader reach to patients. For Beigene, we have been bent on developing world-class oncology treatment both in China and to Chinese patients, said Wang on Thursday at a launch event in Beijing.

The deal marks the second endorsement the Beijing-headquartered start-up has received from a global partner since Merck Serono, the biopharmaceutical division of Merck, signed a licensing and co-development deal with the company in 2013.

BGB-A317 is a type of humanised antibody that belongs to a new class of drugs called PD-1 inhibitors, which are designed to block a mechanism often used by cancer to hide itself and evade detection from the immune system. The drug, which aims to help the body recognise the threat, is being developed as a monotherapy and in combination with others to treat a broad array of solid tumours and blood cancers.

Currently, the therapy is undergoing trials in China to treat bladder cancer and Hodgkin lymphoma, with more than 650 patients enrolled, according to the company.

Preliminary data suggest that BGB-A317 is well tolerated and has anti-tumour activity. We have presented data on over 300 patients at international medical conferences, said John Oyler, co-founder and CEO of BeiGene.

Operating in China since it was founded in 2010, BeiGene is a research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer treatment. The company claims to have around 200 PhD holders among its 700 staff. More than a quarter of them have overseas education experience.

The partnership between Celgene and BeiGene also marks a paradigm shift in Chinas pharmaceutical market, said Sang Guowei, chief architect of the National Special Project on New Drug Innovation. Chinese pharmaceutical companies have grown from licensing in to licensing out. Their gap with international giants is becoming narrower, said Sang.

Nevertheless, some distance remains at the funding and internationalisation level, the industry veteran added.

China is the second largest pharmaceutical market in the world, and is forecast to expand from US$108 billion in 2015 to US$167 billion by 2020, representing annual growth of 9.1 per cent, according to a report last year from the US International Trade Administration.

(c) 2017 Arab Times Kuwait English Daily. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
CELGENE CORPORATION 0.62% 85.7578 Delayed Quote.-17.89%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BEIGENE LTD (ADR)
07/09BEIGENE : Announces Inducement Grants Under NASDAQ Listing Rule 5635(4)
AQ
07/03BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GL
06/20BEIGENE : Provides Development Update and Presents Clinical Data on Zanubrutinib..
AQ
06/15BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/15BeiGene Provides Development Update and Presents Clinical Data on Zanubrutini..
GL
06/08BEIGENE, LTD. : Change in Directors or Principal Officers, Submission of Matters..
AQ
06/06BeiGene to Present at the Goldman Sachs 39th Annual Global Healthcare Confere..
GL
06/05BEIGENE : to Present at the William Blair 2018 Growth Stock Conference
AQ
06/01BeiGene to Present Data on Zanubrutinib and Host an Investor Call from the 23..
GL
05/21BEIGENE LTD (ADR) : Blog Exposure - BeiGene Commenced Phase-3 Trial of Pamiparib..
AC
More news
News from SeekingAlpha
06/303 THINGS IN BIOTECH, JUNE 30 : Aptose Gets Rolling Again; Tesaro Heads To China;.. 
06/21MIRATI THERAPEUTICS : How Much Higher Can This 'Rocket' Go? 
06/193 THINGS IN BIOTECH, JUNE 18 : Some More Good Heme News! 
06/18BeiGene (BGNE) EHA Update On BTK Inhibitor Zanubrutinib And The Clinical Deve.. 
06/18YOUR DAILY PHARMA SCOOP : Selecta Bio Reports Positive, Acceleron And Atara Move.. 
Financials ($)
Sales 2018 114 M
EBIT 2018 -371 M
Net income 2018 -436 M
Finance 2018 925 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 69,9x
EV / Sales 2019 66,3x
Capitalization 8 929 M
Chart BEIGENE LTD (ADR)
Duration : Period :
Beigene Ltd (ADR) Technical Analysis Chart | BGNE | US07725L1026 | 4-Traders
Technical analysis trends BEIGENE LTD (ADR)
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 199 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
John V. Oyler Chairman & Chief Executive Officer
Xiao Bin Wu President
Maggie Liu Head-Operations
Howard Liang Chief Financial & Strategy Officer
Amy C. Peterson Chief Medical Officer-Immuno-Oncology
Sector and Competitors
1st jan.Capitalization (M$)
BEIGENE LTD (ADR)67.00%8 929
GILEAD SCIENCES7.84%100 614
VERTEX PHARMACEUTICALS20.45%45 997
REGENERON PHARMACEUTICALS-2.21%38 951
GENMAB5.93%10 467
NEUROCRINE BIOSCIENCES, INC.32.61%9 250